-
AriBio Expands Alzheimer’s Drug AR1001 Licensing Deal with Samjin to Include China
•
AriBio Co., Ltd, a South Korea-based pharmaceutical company, has announced an expansion of its previous licensing agreement with Samjin Pharmaceutical (KRX: 005500) to include the China market for its Alzheimer’s disease drug candidate, AR1001. The new deal, which grants exclusive marketing rights to the drug in China, is valued at…
-
AriBio Files for Phase III Clinical Trial Approval in China for Alzheimer’s Drug AR1001
•
South Korean clinical-stage biotech AriBio Co. has announced the filing for Phase III clinical trial approval in China for its anti-Alzheimer’s disease (AD) drug candidate, AR1001. The filing is currently under review by the National Medical Products Administration’s Center for Drug Evaluation. Global Phase III Trial Expansion PlansAriBio aims to…
